Stock PHO PHOTOCURE ASA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Photocure ASA

Equities

PHO

NO0010000045

Pharmaceuticals

Market Closed - Oslo Bors
Other stock markets
 10:45:00 2024-04-26 am EDT 		5-day change 1st Jan Change
55.4 NOK +1.84% Intraday chart for Photocure ASA +1.09% -17.80%
Apr. 08 Photocure ASA Announces its Participation in the Congress, and Two Abstract Presentations at the 2024 European Association of Urology Congress in Paris, France CI
Mar. 28 Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 1,045 1,963 2,846 2,769 2,895 1,502 1,502 -
Enterprise Value (EV) 1 937.8 1,837 2,562 2,483 2,639 1,827 1,246 1,194
P/E ratio -28.2 x 61.3 x -117 x -89.3 x -40.2 x 6,740 x 1,305 x 23.2 x
Yield - - - - - - - -
Capitalization / Revenue 5.75 x 6.97 x 11.1 x 7.68 x 7.73 x 4.09 x 3.03 x 2.51 x
EV / Revenue 5.17 x 6.53 x 9.99 x 6.89 x 7.05 x 4.09 x 2.52 x 2 x
EV / EBITDA -89.3 x 31.2 x -655 x 136 x -107 x 32.9 x 36.4 x 10.4 x
EV / FCF - - -16.9 x 113 x -469 x - 166 x 16.7 x
FCF Yield - - -5.9% 0.89% -0.21% - 0.6% 5.99%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 21,764 21,930 26,702 26,960 27,106 27,106 27,106 -
Reference price 2 48.00 89.50 106.6 102.7 106.8 55.40 55.40 55.40
Announcement Date 2/27/19 2/27/20 3/3/21 2/23/22 2/23/23 2/21/24 - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 181.5 281.6 256.5 360.5 374.5 446.2 495 597.2
EBITDA 1 -10.5 58.95 -3.912 18.3 -24.63 55.49 34.19 115.3
EBIT 1 -23.7 42.74 -23.2 -5.826 -49 27.81 3.877 83.99
Operating Margin -13.06% 15.18% -9.05% -1.62% -13.09% 6.23% 0.78% 14.06%
Earnings before Tax (EBT) 1 -36.72 45.9 -33.23 -31.66 -71.13 9.738 1.377 81.99
Net income 1 -36.74 31.83 -22.4 -30.9 -71.86 0.267 0.9877 64.6
Net margin -20.24% 11.31% -8.73% -8.57% -19.19% 0.06% 0.2% 10.82%
EPS 2 -1.700 1.460 -0.9100 -1.150 -2.660 0.0100 0.0424 2.385
Free Cash Flow 1 - - -151.2 21.99 -5.627 - 7.5 71.5
FCF margin - - -58.95% 6.1% -1.5% - 1.52% 11.97%
FCF Conversion (EBITDA) - - - 120.16% - - 21.94% 62.01%
FCF Conversion (Net income) - - - - - - 759.34% 110.68%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/27/19 2/27/20 3/3/21 2/23/22 2/23/23 2/21/24 - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 90.44 87.4 94.52 81.6 100.6 106.8 94.94 106.2 144.3 107.5 115 114.5 147 117 129
EBITDA 1 5.834 -0.2 -5.469 -13.88 1.4 4.7 -16.87 -1.2 23.39 3.339 29.92 3 30 - 11
EBIT 1 -0.248 -6.344 -11.5 -19.88 -4.6 -1.4 -23.1 -7.7 16.84 -3.852 22.48 -5 23 -7 4
Operating Margin -0.27% -7.26% -12.17% -24.36% -4.57% -1.31% -24.33% -7.25% 11.67% -3.58% 19.54% -4.37% 15.65% -5.98% 3.1%
Earnings before Tax (EBT) 1 -7.565 -11.4 -33.03 -27.26 -9.053 -6.262 -28.56 -10.1 11.96 -8.666 16.55 -5.5 25 -5 6
Net income 1 -10.61 -7.301 -28.15 -21.98 -18.46 -9.932 -21.48 -11.7 4.311 -4.788 12.48 -4.5 20 -4 5
Net margin -11.74% -8.35% -29.78% -26.94% -18.35% -9.3% -22.63% -11.02% 2.99% -4.45% 10.85% -3.93% 13.61% -3.42% 3.88%
EPS 2 -0.4000 -0.2700 -1.050 -0.8200 -0.6800 -0.3700 -0.7900 -0.4300 0.1600 -0.1800 0.4600 -0.0800 0.7200 -0.1500 0.1700
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 8/11/21 11/17/21 2/23/22 5/11/22 8/10/22 11/2/22 2/23/23 5/10/23 8/9/23 11/8/23 2/21/24 - - - -
1NOK in Million2NOK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - - -
Net Cash position 1 107 125 285 285 256 239 256 308
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - -151 22 -5.63 - 7.5 71.5
ROE (net income / shareholders' equity) -18.6% 16.5% -6.25% -6.11% -14.9% -7.75% -0.65% 14.4%
ROA (Net income/ Total Assets) - - -4.34% -3.95% - -1.1% 2.5% 10.6%
Assets 1 - - 516.7 782.8 - 769.7 39.51 609.4
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 1.63 - 167 3.7 3.61 3.5 3 2.5
Capex / Sales 0.9% - 65.03% 1.03% 0.96% 0.75% 0.61% 0.42%
Announcement Date 2/27/19 2/27/20 3/3/21 2/23/22 2/23/23 2/21/24 - -
1NOK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Photocure ASA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
55.4 NOK
Average target price
86 NOK
Spread / Average Target
+55.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PHOTOCURE ASA Stock Photocure ASA
-17.80% 136M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PHO Stock
  4. Financials Photocure ASA